Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

Emerging treatment landscape of non-muscle invasive bladder cancer

Articolo
Data di Pubblicazione:
2022
Citazione:
Emerging treatment landscape of non-muscle invasive bladder cancer / Valenza, C., Antonarelli, G., Giugliano, F., Aurilio, G., Verri, E., Briganti, A., Curigliano, G., Necchi, A.. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 22:6(2022), pp. 717-734. [10.1080/14712598.2022.2082869]
Abstract:
Introduction: Non-muscle invasive bladder cancer (NMIBC) accounts for 70–75% of all bladder cancers and is a heterogeneous disease characterized by a wide spectrum of recurrences and progression. Adjuvant treatment for intermediate- and high-risk NMIBC is mainly represented by Bacillus Calmette Guerin (BCG). However, 20%–40% of patients develop disease recurrences or persistence following BCG treatment and are classified as “BCG unresponsive’ (BCGu), thus representing a therapeutic challenge due to their worse prognosis and unavailability of effective intravesical treatments. Areas covered: We provide an overview of completed and ongoing clinical trials assessing the role of innovative immunological and target agents in patients with BCGu and BCG naive (BCGn) NMIBCs. New treatment options are emerging, demonstrating promising clinical activity, namely, pembrolizumab, atezolizumab, oportuzumab monatox, nadofaragene firadenovec, and N-803. Expert opinion: The increasing number of newer therapeutic agents for patients with NMIBC poses challenges regarding the choice of the most suited treatment option for each patient and the best treatment sequence, given their diverse mechanisms of action and varying degrees of activity. Tailored treatment approaches are advocated, based on a deeper comprehension of disease features, available therapies, patient’s characteristics, and consequently, on the identification and validation of prognostic and predictive biomarkers.
Tipologia CRIS:
1.1.1 Articolo in rivista - Review
Elenco autori:
Valenza, C.; Antonarelli, G.; Giugliano, F.; Aurilio, G.; Verri, E.; Briganti, A.; Curigliano, G.; Necchi, A.
Autori di Ateneo:
BRIGANTI ALBERTO
NECCHI ANDREA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/208999
Pubblicato in:
EXPERT OPINION ON BIOLOGICAL THERAPY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.11.1.0